AI Article Synopsis
- * A new approach using lipid-coated calcium carbonate nanoparticles (LCC-DOX/miR-375 NPs) was developed, which combines DOX with the tumor-suppressing microRNA miR-375, showing improved anti-tumor effects and reversing drug resistance.
- * In laboratory and animal tests, these nanoparticles demonstrated increased drug accumulation and effective cancer-fighting properties, suggesting a promising new strategy for treating drug-resistant HCC.
Article Abstract
Hepatocellular carcinoma (HCC) is a prevalent and lethal disease that is characterized by drug resistance. Doxorubicin (DOX) is a widely used chemotherapeutic drug and miR-375 has been shown to be a tumor suppressor in HCC. Here, we reported that miR-375 and DOX co-loaded into lipid-coated calcium carbonate nanoparticles (LCC-DOX/miR-375 NPs), enhanced the anti-tumor effects through combination therapy, and were highly effective in reversing drug resistance in HCC. LCC-DOX/miR-375 NPs were prepared by a reverse microemulsions method. In vitro, LCC-DOX/miR-375 NPs exhibited enhanced intracellular accumulation, pH-sensitive DOX release and potent cytotoxicity. In vivo, LCC-DOX/miR-375 NPs showed efficient antitumor effect both in xenograft and primary HCC murine models. Our results showed that the LCC-DOX/miR-375 nanoparticles provide a novel strategy to overcome the drug resistance and promote addictive effect between miR-375 and DOX in HCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.nano.2017.05.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!